Correction to company release dated January 26, 2018 - Conversion of FIT Biotech Oy's Convertible Capital Notes into shares - number of shares

FIT Biotech Oy

Company release January 29, 2018 at 11:35 AM EET

Correction to company release dated January 26, 2018 - Conversion of FIT Biotech Oy's Convertible Capital Notes into shares - number of shares

Due to the conversion of the Convertible Capital Notes, the Company transfers 20,000,000 K shares owned by the Company to ABO.  On company release January 26, 2018, the number of shares was incorrect 100,000 shares.

FIT BIOTECH OY

Board of Directors

For further information:
CEO Erkki Pekkarinen
Tel: +358440270080
E-mail: erkki.pekkarinen@fitbiotech.com

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media